Nuvo Research

 
Stock Quotes for Nuvo Research top ^
  • Industry: Conglomerates
  • Sector: Industrials
  • Stock Style: Mid Value
Sign-up for abirlanuvo investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Value
Sign-up for nri investment picks
  • Industry: Conglomerates
  • Sector: Industrials
  • Stock Style: Mid Value
Sign-up for 500303 investment picks

 
News Articles for Nuvo Research top ^
2013/3/5
Nuvo Research announces FDA response to PENNSAID® 2% NDA Canada NewsWire MISSISSAUGA, ON, March 5, 2013 /CNW/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt, the Pharmaceuticals Business of Covidien (NYSE:COV) , has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%). In the letter, the FDA requires that Mallinckrodt successfully complete a pharmacokinetic study comparing PENNSAID 2% to original PENNSAID 1.5%. Similar pharmacokinetic studies submitted by Mallinckrodt with the NDA were not acceptable to the FDA because reserve samples were not retained at the clinical site.
Sign-up for Nuvo Research announces FDA response to PENNSAID® 2% NDA investment picks
2013/3/5
MISSISSAUGA, ON , March 5, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that its U.S. licensing partner, Mallinckrodt , the Pharmaceuticals Business of Covidien (NYSE:COV) , has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following the review of Mallinckrodt's New Drug Application (NDA) for diclofenac sodium topical solution, 2% w/w (PENNSAID 2%). In the letter, the FDA requires that Mallinckrodt successfully complete a pharmacokinetic study comparing PENNSAID 2% to original PENNSAID 1.5%. Similar pharmacokinetic studies submitted by Mallinckrodt with the NDA were not acceptable to the FDA because reserve samples were not retained at the clinical site.
Sign-up for Nuvo Research announces FDA response to PENNSAID® 2% NDA investment picks
2013/1/29
Nuvo Research announces settlement agreement with Apotex in PENNSAID® generic litigation Canada NewsWire MISSISSAUGA, ON, Jan.
Sign-up for Nuvo Research announces settlement agreement with Apotex in PENNSAID® generic litigation investment picks
2013/1/29
MISSISSAUGA, ON , Jan.
Sign-up for Nuvo Research announces settlement agreement with Apotex in PENNSAID® generic litigation investment picks
2013/3/18
MISSISSAUGA, ON , March 18, 2013 /PRNewswire/ - Nuvo Research Inc. (Nuvo) (TSX:NRI) announced today that a Question and Answer document has been posted on its website to provide additional information to Nuvo shareholders regarding the regulatory status of Pennsaid 2% in the United States .
Sign-up for Nuvo Research provides additional information regarding Pennsaid 2% investment picks
2013/4/23
Nuvo Research announces European launch of Pliaglis® by Galderma Canada NewsWire MISSISSAUGA, ON, April 23, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.
Sign-up for Nuvo Research announces European launch of Pliaglis® by Galderma investment picks
2013/5/1
Nuvo Research announces 2013 First Quarter Results Canada NewsWire MISSISSAUGA, ON, May 1, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the first quarter ended March 31, 2013 .
Sign-up for Nuvo Research announces 2013 First Quarter Results investment picks
2013/4/19
Nuvo Research announces scientific presentation at the Annual Meeting of the American Medical Society for Sports Medicine Canada NewsWire Data Evaluating Synera ® for the Treatment of Shoulder Impingement Syndrome MISSISSAUGA, ON, April 19, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that researchers presented scientific data related to Synera ® (70 mg lidocaine/ 70 mg tetracaine) topical patch at the 22 nd Annual Meeting of the American Medical Society for Sports Medicine (AMSSM) in San Diego , California.
Sign-up for Nuvo Research announces scientific presentation at the Annual Meeting of the American Medical Society for Sports Medicine investment picks
2013/4/23
MISSISSAUGA, ON , April 23, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.
Sign-up for Nuvo Research announces European launch of Pliaglis® by Galderma investment picks
2013/5/1
MISSISSAUGA, ON , May 1, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the first quarter ended March 31, 2013 .
Sign-up for Nuvo Research announces 2013 First Quarter Results investment picks
2013/3/11
MISSISSAUGA, ON , March 11, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Laboratories, L.P., the U.S. affiliate of Galderma Pharma, S.A. (Galderma), today announced the U.S. launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%.  Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.
Sign-up for Nuvo Research announces U.S. launch of Pliaglis® by Galderma investment picks
2013/4/19
Data Evaluating Synera ® for the Treatment of Shoulder Impingement Syndrome MISSISSAUGA, ON , April 19, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain today announced that researchers presented scientific data related to Synera ® (70 mg lidocaine/ 70 mg tetracaine) topical patch at the 22 nd Annual Meeting of the American Medical Society for Sports Medicine (AMSSM) in San Diego, California .
Sign-up for Nuvo Research announces scientific presentation at the Annual Meeting of the American Medical Society for Sports Medicine investment picks
2013/4/23
Nuvo Research Inc. (TSX:NRI) , a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and Galderma Pharma, S.A. (Galderma), today announced the European launch of Pliaglis (lidocaine and tetracaine) Cream 7%/7%. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialized in dermatology.
Sign-up for Nuvo Research Announces European Launch of Pliaglis® by Galderma investment picks
2013/5/7
Nuvo Research to Complete Share Consolidation Canada NewsWire MISSISSAUGA, ON, May 7, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) (the "Company" or "Nuvo"), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it will proceed with its proposed share consolidation (the "Consolidation"), as approved by the shareholders of Nuvo at the annual and special meeting held on May 15, 2012 , on the basis of 65 pre-Consolidation common shares for one (1) post-Consolidation common share.
Sign-up for Nuvo Research to Complete Share Consolidation investment picks
2013/5/7
MISSISSAUGA, ON , May 7, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) (the "Company" or "Nuvo"), a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it will proceed with its proposed share consolidation (the "Consolidation"), as approved by the shareholders of Nuvo at the annual and special meeting held on May 15, 2012 , on the basis of 65 pre-Consolidation common shares for one (1) post-Consolidation common share.
Sign-up for Nuvo Research to Complete Share Consolidation investment picks
2013/5/16
Nuvo Research Announces Scientific Presentation at the Annual Meeting of the American Association of Immunologists Canada NewsWire Data Evaluating WF10's Therapeutic Impact on Signs and Symptoms of Experimentally Induced Rheumatoid Arthritis in Mice MISSISSAUGA, ON, May 16, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI and Nuvo presented scientific data related to WF10's therapeutic impact on signs and symptoms of experimentally induced rheumatoid arthritis in mice at the 100 th Annual Meeting of The American Association of Immunologists (AAI) in Honolulu , Hawaii, U.S. Compared to the placebo group, animals treated with WF10 showed a reduction of the
Sign-up for Nuvo Research Announces Scientific Presentation at the Annual Meeting of the American Association of Immunologists investment picks
2013/3/11
Nuvo Research announces U.S. launch of Pliaglis® by Galderma Canada NewsWire Important Safety Information Indication: PLIAGLIS® (lidocaine and tetracaine) Cream 7% / 7% is indicated for use on intact skin in adults to provide topical local analgesia for superficial dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal.
Sign-up for Nuvo Research announces U.S. launch of Pliaglis® by Galderma investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Nuvo Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Nutrition Research  |  Next: NV Energy